


La Merie - Mozilla Firefox


Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.pipelinerreview.com/database/users/login

La Merie



La Merie
Business Intelligence



Login

Username:

Password:

Report Code:

Remember Username?
[Forgot Password?](#)

If you have problems logging in, please contact us at
support@lamerie.com

× Encontrar: TPI

↓ Sigüente ↑ Anterior

Resaltar todo

Coincidencia de mayúsculas/minúsculas

Se alcanzó el final de la página, se continúa desde el principio

La Merie - Mozilla Fi... Sample Pages Antib... ES 15:19

La Merie - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.pipelinereview.com/database/projects

La Merie

La Merie Business Intelligence

Dear WalFix,
Your account will expire on January 2, 2011.
If you encounter any problems or have questions, please contact us at support@pipelinereview.com

LOGOUT SEARCH EXPORT REPORTS PROJECTS

Print

Projects

Id	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
14353	2010-11-03	Trastuzumab (TPI)	Vascular endothelial growth factor (VEGF) inhibitor	Rec humanized mab, biosimilar of Avastin (bevacizumab)	Antibody	Therapeutic Proteins Inc (TPI and subsidiary TPL)	United States	Oncology	Cancer	Preclinical	
14352	2010-11-03	Cetuximab (TPI)	Epidermal growth factor receptor (EGFR) inhibitor	Monoclonal antibody (cetuximab biosimilar)	Antibody	Therapeutic Proteins Inc (TPI and subsidiary TPL)	United States	Oncology	Metastatic colorectal and head and neck cancer	Preclinical	
14351	2010-11-03	Infliximab (TPI)	Tumor necrosis factor (TNF) alpha antagonist	Rec chimeric mab (biosimilar of infliximab)	Antibody	Therapeutic Proteins Inc (TPI and subsidiary TPL)	United States	Rheumatoid & autoimmune	Rheumatoid arthritis	Preclinical	
14350	2010-11-03	Rituximab (TPI)	CD20	Rec chimeric mab. Biosimilar of rituximab (Rituxan)	Antibody	Therapeutic Proteins Inc (TPI and subsidiary TPL)	United States	Oncology	Hodgkin's lymphoma	Preclinical	
14349	2010-11-03	Etanercept (TPI)	Tumor necrosis factor (TNF) alpha antagonist	Rec fusion protein, biosimilar of Enbrel (etanercept)	Antibody	Therapeutic Proteins Inc (TPI and subsidiary TPL)	United States	Rheumatoid & autoimmune	Rheumatoid arthritis	Preclinical	
14342	2010-11-02	Tetabulin Inj; tetanus Immune Globulin	Directly neutralizes toxin excreted by Clostridium tetani, cause of tetanus.	Tetanus human immunoglobulin, S/D treated	Antibody	SK Chemicals	Korea, Republic of	Cardiovascular, blood & acute care	Passive immunization against tetanus (postexposure, prophylaxis & treatment of tetanus)	Market	
			Reduce the risk	Purified, human plasma-					Agammaglobulinemia, Hypogammaglobulinemia, Idiopathic		

Encontrar: TPI

Coincidencia de mayúsculas/minúsculas

ES

15:20

La Merie - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.pipelinerreview.com/database/projects/search

La Merie

La:Merie
Business Intelligence

Dear WalFix,
Your account will expire on **January 2, 2011**.
If you encounter any problems or have questions, please contact us at support@pipelinerreview.com

LOGOUT SEARCH EXPORT REPORTS PROJECTS

Print Export

Search

Search

Clear

Any Word
 All Words
 Exact Phrase
 Advanced Search

Target: All Targets

Territory

- All Countries
- Aaland Islands
- Afghanistan
- Albania
- Algeria
- American Samoa
- Andorra
- Angola

Therapeutic Area

- All Therapeutic Areas
- Cardiovascular, blood & acute care
- Dermatology

Phase

- All Phases
- Market
- sBLA

Id	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase
Projects 0 to 0 of 0										

La Merie - Mozilla Fi... Sample Pages Antib... ES 9:49

La Merie - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.pipelinerreview.com/database/projects/search

La Merie

La Merie

Dear WalFix,
Your account will expire on January 2, 2011.
If you encounter any problems or have questions, please contact us at support@pipelinerreview.com

LOGOUT SEARCH EXPORT REPORTS PROJECTS

Print Export

Search

Search

Clear

Any Word All Words Exact Phrase Advanced Search

Target: All Targets

Territory

- All Countries
- Aaland Islands
- Afghanistan
- Albania
- Algeria
- American Samoa
- Andorra
- Angola

Therapeutic Area

- All Therapeutic Areas
- Cardiovascular, blood & acute care
- Dermatology

Phase

- All Phases
- Market
- sBLA

Id	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
13988	2010-09-10	FM202; FM-202	Interleukin-12 and -23 (IL-12; IL-23)	Monoclonal antibody	Antibody	Fenta Pharmaceuticals	United States	Dermatology	Psoriasis	Preclinical	
12307	2010-01-28	Anti-FcRn	Neonatal Fc receptor (FcRn)	Antibody	Antibody	Biogen Idec	United States	Dermatology	Pemphigus	Preclinical	
12219	2010-10-14	HD203; HD-203	TNF antagonist	Biosimilar of etanercept from Amgen & Pfizer (acquired Wyeth)	Antibody	Dream Pharma (a Hanwha company)	Korea, Republic of	Dermatology	Psoriasis	I	
12185	2010-09-16	KSCD11a	CD11a	Rec humanized mab based on Dynamic Cross Linking (DXL) technology. Formulated for topical use as a lotion or in patches	Antibody	InNexus Biotechnology	Canada	Dermatology	Psoriasis	Preclinical	
				Monoclonal antibody for							

La Merie - Mozilla Fi... Sample Pages Antib... ES 9:50

La Merie - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.pipelinereview.com/database/projects/search

La Merie

La Merie Business Intelligence

LOGOUT SEARCH EXPORT REPORTS PRO...

Search

Clear

Any Word All Words Exact Phrase Adv

Target: All Targets

Id	Last Update	Project	Target
13988	2010-09-10	FM202; FM-202	Interleukin-23 (IL-23)
12307	2010-01-28	Anti-FcRn	Neonatal receptor
12219	2010-10-14	HD203; HD-203	TNF-α
12185	2010-09-16	KSCD11a	CD11a

View Project [12185]

Last Update: 2010-09-16

KSCD11a

Target: CD11a

Class of Compound: Rec humanized mab based on Dynamic Cross Linking (DXL) technology. Formulated for topical use as a lotion or in patches

Category: Antibody

Company: InNexus Biotechnology

Territory: Canada

Therapeutic Area: Dermatology

Indication: Psoriasis

Phase: Preclinical

Administration:

Drug Delivery: Dermal permeating Transmab technology

Status: Active

Approval US:

Approval UE:

Approval RoW:

Antibody Tech: Dynamic Cross Linking (DXL(TM)) technology

Protein Tech:

DNA Tech:

RNA Tech:

Cell Tech:

Vaccine Tech:

Partnering:

News

Date	Title	Comments
2010-01-06	InNexus Biotechnology PR Jan 5, 2010	It has developed a new psoriasis product based on its proprietary dermal permeating Transmab technology

Files

No files

Dear WalFix,
Your account will expire on January 2, 2011.
please contact us at support@pipelinereview.com

Print Export

Indication	Phase	
Psoriasis	Preclinical	
Amphiguis	Preclinical	
Psoriasis	I	
Psoriasis	Preclinical	

La Merie - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.pipelinerreview.com/database/projects/search

La Merie

La Merie
Business Intelligence

Dear WalFix,
Your account will expire on **January 2, 2011**.
If you encounter any problems or have questions, please contact us at support@pipelinerreview.com

LOGOUT SEARCH EXPORT REPORTS PROJECTS

Print Export

Search

Search

Clear

Any Word All Words Exact Phrase Advanced Search

Target: All Targets

All Targets
 Amyloid Beta and Tau Targeted Therapy of Alzheimer's Disease
 Anti-Infective Antibodies
 Antibody-Drug-Conjugates (ADC)
 B7-CD28/CTLA-4 Pathway
 Biosimilar & Biobetter/Biosuperior Antibodies
 BlyS, BAFF & APRIL Antagonists
 c-MET/HGF Inhibitors
 CD19 Antibodies
 CD20 Antibodies
 CD22 Antibodies
 CD3 Antagonists
 CD30 Antibodies
 CD40/L Agonists and Antagonists
 CEA Antibodies
 Complement CSa Receptor Antagonists
 EGF-R Agonists and Antagonists
 EpCAM Antagonists
 FGF-R Agonists & Antagonists
 GM-CSF Antibodies

Territory
 All Countries
 Aaland Islands
 Afghanistan
 Albania
 Algeria
 American Samoa
 Andorra
 Angola

Therapeutic Area
 All Therapeutic Areas
 Cardiovascular, blood & acute care
 Dermatology

Phase
 All Phases
 Market
 sBLA

Id	Date	Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase
14353		Humanized mAb, similar to Avastin (pamperizumab)	Antibody	Therapeutic Proteins Inc (TPI and subsidiary TPL)	United States	Oncology	Cancer	Preclinical
14352		Humanized antibody (pamperizumab biosimilar)	Antibody	Therapeutic Proteins Inc (TPI and subsidiary TPL)	United States	Oncology	Metastatic colorectal and head and neck cancer	Preclinical
14351		Humanized mAb (pamperizumab biosimilar)	Antibody	Therapeutic Proteins Inc (TPI and subsidiary TPL)	United States	Rheumatoid & autoimmune	Rheumatoid arthritis	Preclinical
14350	2010-11-03	Rituximab (TPI)	CD20	Biosimilar of rituximab (Rituxan)	United States	Oncology	Hodgkin's lymphoma	Preclinical
14349	2010-11-03	Etanercept (TPI)	Tumor necrosis factor (TNF) alpha antagonist	Rec fusion protein, biosimilar of Enbrel (etanercept)	United States	Rheumatoid & autoimmune	Rheumatoid arthritis	Preclinical

La Merie - Mozilla Firefox Sample Pages Antib... ES 9:51

La Merie - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.pipelinerreview.com/database/projects/search

La Merie

Dear WalFix,
Your account will expire on January 2, 2011.
If you encounter any problems or have questions, please contact us at support@pipelinerreview.com

LOGOUT SEARCH EXPORT REPORTS PROJECTS

Search Print Export

Any Word All Words Exact Phrase Advanced Search

Target:

Territory
 All Countries
 Aaland Islands
 Afghanistan
 Albania
 Algeria
 American Samoa
 Andorra
 Angola

Therapeutic Area
 All Therapeutic Areas
 Cardiovascular, blood & acute care
 Dermatology

Phase
 All Phases
 Market
 sBLA

Id	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
12858	2010-04-22	HuMax-cMet	cMet oncogenic protein	Rec fully human IgG1 monoclonal antibody	Antibody	Genmab	Denmark	Rheumatoid & autoimmune	Breast, lung, pancreatic, ovarian, prostate, renal, gastric and colorectal cancers	0	
12416	2010-02-16	R13/28 anti-MET antibody (OncoMed)	Two epitopes on c-MET	Rec fully human bispecific mab	Antibody	OncoMed Pharmaceuticals	Switzerland	Oncology	Cancer	Research	
12349	2010-02-05	ABX101; ABX-101	Hepatocyte growth factor/scatter factor (HGF/SF) inhibitor	Rec humanized mab	Antibody	Abxign	Korea, Republic of	Oncology	Cancer	Preclinical	
12347	2010-10-01	AV-299; SCH900105; SCH-900105	Hepatocyte growth factor/scatter factor (HGF/SF) inhibitor	Rec humanized antibody (XOMA technology)	Antibody	AVEO Pharmaceuticals	United States	Oncology	Non-small cell lung cancer (NSCLC) plus gefitinib	II	
			Human hepatocyte						Ovarian Epithelial		

La Merie - Mozilla Fi... Sample Pages Antib... ES 9:52

La Merie - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.pipelinereview.com/database/projects/reports

La Merie

La Merie Business Intelligence

Dear WalFix,
Your account will expire on **January 2, 2011**.
If you encounter any problems or have questions, please contact us at support@pipelinereview.com

LOGOUT SEARCH EXPORT REPORTS PROJECTS

Export Reports Print Export

Date: to: Custom Report

Territory

- All Countries
- Aaland Islands
- Afghanistan
- Albania
- Algeria
- American Samoa
- Andorra
- Angola

Target:

All Targets

Keyword

Any Word All Words Exact Phrase

Therapeutic Area

- Dermatology
- Gastrointestinal
- Genitourinary, renal & gynecology

Phase

- All Phases
- Market
- sBLA

Id	Project	Target	Class of Compound	Company	Category	Indication	R&D Stage	Message
650	CIMZIA; certolizumab pegol; CDP-870	TNF-alpha (soluble and membrane bound)	Rec humanized Fab' fragment conjugated with 40 kD PEG	UCB Pharma (ex Celltech)	Antibody	Moderate to severe Crohn's disease and all approved indications	Market	
653	Tysabri; Antegren; natalizumab; AN-100226	Alpha4/beta1/7 integrin	Rec humanized IgG4 mab	Biogen-IDEC & Elan	Antibody	Crohn's disease	Market	
656	Humira Pen; adalimumab; D-2E7; LU-200134	TNF alpha antagonist	Rec fully human IgG1 mab	Abbott & Eisai	Antibody	Moderate to severe Crohn's disease	Market	
661	Remicade; infliximab	TNF alpha antagonist	Rec chimeric IgG1 mab	Centocor (J&J) & Merck & Co. (acquired Schering-Plough) & Mitsubishi	Antibody	Moderately to severely active ulcerative colitis	Market	

La Merie - Mozilla Fi... Sample Pages Antib... ES 9:53